Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Alexion recalled a single lot of Orphan drug Soliris eculizumab due to the presence of visible particles in a limited
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury